Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase 1/2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1

Conditions

Sarcoma 2Pancreatic Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × olaratumab × Clear all
NCT03086369 2022-06-28

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
184 enrolled 22 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02659020 2022-05-09

ANNOUNCE 2

Eli Lilly and Company

Phase 1/2 Completed
310 enrolled 33 charts
Sarcoma

Sarcoma

NCT01185964 2017-04-14

A Study of Olaratumab in Soft Tissue Sarcoma

Eli Lilly and Company

Phase 1/2 Completed
148 enrolled 21 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡